Introduction
Malignant gliomas originate and develop through cumulative, growth-advantageous, stage-speci®c genetic alterations including loss of heterozygosity (LOH) for chromosome 17p, mutation of the p53 gene, overexpression of the platelet-derived growth factor-a receptor (PDGFRa), allelic losses of chromosomes 22q, 9p, 13q, and 19q, ampli®cation and rearrangement of the epidermal growth factor receptor (EGFR), and monosomy of chromosome 10 (reviewed in Louis and Cavenee, 1997) . Hemizygous and homozygous deletions involving chromosome 9p are among the most common abnormalities in high grade malignant gliomas, suggesting the presence of one or more tumor suppressor genes within that region (James et al., 1993; Olopade et al., 1992) . Most such deletions occur at 9p21, the chromosomal region containing the CDKN2A locus, which encodes the cyclin-dependent kinase inhibitor (CKI), p16
INK4a (Serrano et al., 1993) . A considerable body of evidence implicates the tumor suppressor gene CDKN2A (Kamb et al., 1994; Nobori et al., 1994; Serrano et al., 1993) , as a critical target of the 9p21 deletions (Sherr, 1996) .
It has recently been shown that the human and murine CDKN2A genes also contain an alternate reading frame encoding an entirely dierent protein product, designated human p16b (Duro et al., 1995; Mao et al., 1995; Stone et al., 1995) and murine p19 ARF (Quelle et al., 1995) . Several lines of evidence suggest that p16b may also be a growth suppressor of a variety of tumors including malignant gliomas. First, it maps approximately 15 kb upstream of exon 1a of CDKN2A, a region frequently deleted in gliomas, and there is at least one report of a deletion eliminating exon 1b while preserving p16
INK4a coding sequence in a malignant glioma xenograft (Jen et al., 1994) . Second, overexpression of murine p19 ARF induced G 1 /S and G 2 / M cell cycle arrests of NIH3T3 ®broblasts (Quelle et al., 1995 (Quelle et al., , 1997 and transfection of human p16b cDNA caused G 1 /S arrest and growth suppression of head and neck carcinoma cells , although the pathway by which this is accomplished has not yet been de®ned Quelle et al., 1995 Quelle et al., , 1997 INK4a and p16b) has been found mutated in human tumors (Sherr, 1996) . Fourth, although mice with a targeted deletion of the CDKN2A gene were found to develop spontaneous tumors at an early age and to be highly sensitive to carcinogenic treatments, the relative roles of the murine p16
INK4a and p19 ARF remained unclear since both products were eliminated (Serrano et al., 1996) .
Here, we sought to determine if human p16b can suppress glioma cell growth. We transfected wild-type and mutant p16b into malignant glioma cells with de®ned p16
INK4a and pRB endogenous backgrounds. to inhibit pRB phosphorylation both in vitro and in vivo, consistent with the interpretation that RB is not in its primary pathway. We also show that seven CDKN2A alleles containing exon 2 naturally-occurring glioma-derived mutations (Arap et al., 1997) retained the growth suppressive activity of wild-type p16b. Taken together, these data demonstrate that p16b has growth suppressive activity mediated through an RB-independent pathway and that point mutations in the shared CDKN2A exon 2 appear to exclusively target p16
INK4a
, at least in malignant glioma cells.
Results

p16b suppresses glioma cell growth
Human malignant glioma-derived cell lines having de®ned CDKN2A/RB pathways were used as recipients for gene transfer. U-87MG and U-251MG are endogenously CDKN2A (a and b) . cDNAs corresponding to the CDKN2A (a and b) and CDKN2B transcripts in LN-319 cells have been sequenced and found to be wild-type.
To test the hypothesis that p16b is a glioma cell growth suppressor, we introduced a wild-type CDKN2Ab full-length cDNA into U-87MG, U-251MG, and LN-319 cells. After completion of drug selection, we compared the resulting growth suppressive eect to that of empty vector, wild-type CDKN2Aa cDNA (encoding p16
INK4a
), and wild-type CDKN2B (encoding p15 INK4b ). All plasmids were constructed in the same mammalian expression vector (pcDNA3) under the control of a CMV promoter. Growth suppression was quanti®ed by comparing the relative number of drug resistant cells obtained with each construct, setting vector control to 100% in each case. In each of the glioma cell lines studied here, the biological eects observed upon replacement of either p16
INK4a or p15 INK4b were remarkably similar. In the CDKN2A-null cell lines (U-87MG and U-251MG), the replacement of CDKN2Ab resulted in growth suppression (t-test, P50.01 in each case). Despite the marked growth suppression observed in LN-319 cells (endogenously wild-type CDKN2Aa and b, RB-negative) upon introduction of the exogenous CDKN2Ab cDNA (t-test, P50.01), no signi®cant negative growth eects were observed upon transfer of either CDKN2Aa (t-test, P=0.50) or CDKN2B (ttest, P=0.39) genes, relative to control vector. These data were obtained with bulk populations of transfected cells harvested 7 ± 10 days posttransfection (Figure 1a ) to minimize the possibility of clonal variation. To determine the long term eect of CDKN2Ab in RB-negative LN-319 cells, we used a clonagenic survival assay ( Figure 1b) . In this assay, colony inhibition observed four weeks post CDKN2Ab transfection was remarkably consistent with the overall growth suppressive eects of p16b in bulk LN-319 transfected populations. Again, empty vector, CDKN2Aa, and CDKN2B gene transfer were used as assay controls, and yielded comparable numbers of colonies ( Figure 1b ).
p16b function is RB-independent
Most available in vitro functional assays for CKI activities use baculoviral-derived CDKs produced in insect cells. Thus, we ®rst addressed the question of whether p16b speci®cally binds to CDK4, the CDK that broadly de®nes the INK4A family, produced in mammalian cells. For this purpose, we used the glioblastoma cell line LN-Z308, which has a marked ampli®cation and overexpression of the CDK4 gene (*20-fold, unpublished observations). Metabolically labeled LN-Z308 cell lysate was incubated with either GST alone (negative control), recombinant GSTp16 INK4a (positive control), or GST-p16b in a CDK4 -beads, or GST-p16b-beads. Next, the admixtures were taken for sequential GST-beads precipitation and separation by 4 ± 20% gradient SDS ± PAGE. Extracts from U-251MG, LN-319 cells (which contain normal amounts of CDK4) and LN-Z308 cells (which contains a marked CDK4 ampli®cation/overexpression). Under the conditions of this assay, recombinant GSTp16
INK4a
, but not either GST alone or GST-p16b, is clearly able to bind and coprecipitate human CDK4. Similar results were observed twice. (b) In vitro inhibition of RB phosphorylation assay. Either GST alone or human recombinant GST-p16
and GST-p16b fusion proteins were assayed for their ability to speci®cally inhibit the kinase activities CDK4/cyclin D1, CDK6/ cyclin D1, or CDK2/cyclin A, using the recombinant GST-RB SspI-End (SE, residues 768 ± 928) as a substrate. Samples were separated by 4 ± 20% gradient SDS ± PAGE. Under the conditions of this assay, fusion GST-p16
, but not GST alone or GSTp16b, was able to inhibit pRB/SE phosphorylation by CDK4/ cyclin D1 or by CDK6/cyclin D1. None of the products was able to inhibit CDK2/cyclin A kinase activity. Similar results were observed twice binding assay. Under these conditions, recombinant GST-p16b was unable to bind to mammalian CDK4 (Figure 2a ). Lysates from metabolically labeled U-251MG, and LN-319 cells, which contain normal amounts of CDK4 and thus are below the sensitivity level in this assay, were also used as additional controls. Thus, p16b does not appear to bind to the native human CDK4 protein.
In order to determine whether CDK/cyclin complexes are direct targets of the human CDKN2Ab product, we tested the ability of recombinant GSTp16b fusion proteins to inhibit either CDK4/cyclin D1 or CDK6/cyclin D1 (the only known targets of p16 INK4a ), using the retinoblastoma protein as a substrate in vitro. GST alone was used as a negative control and recombinant INK4a was used as a positive control for inhibition of pRB phosphorylation by either CDK4/cyclin D1 or CDK6/cyclin D1 complexes. At concentrations in which p16
INK4a completely inhibited these kinase activities (Arap et al., 1997) , neither CDK4/cyclin D1 nor CDK6/cyclin D1 activities were inhibited indicating that they are not direct targets of p16b. Titrations were performed to normalize for equal input of each recombinant product and to determine whether the lack of p16b inhibitory activity was due to dosage dierences. Similar results were observed even at p16b relative concentrations up to fourfold higher than those of p16
INK4a (data not shown). Moreover, recombinant GST-p16b was also not a direct inhibitor of the CDK2/cyclin A complex, which was also resistant to inhibition by GST-p16
Therefore, p16b appears unable to inhibit known Dtype cyclin kinase activities (Figure 2b ).To establish kinetics of inhibition and to assess the magnitude of pRB phosphorylation during cell growth arrest, we used an assay of the in vivo inhibition of RB phosphorylation (Arap et al., 1997) . Time courses were performed after transfection of either empty control vector, CDKN2Aa (p16 INK4a ), CDKN2Ab (p16b), or CDKN2B (p15 INK4b ) expression plasmids, each of which was cotransfected with limiting amounts of pCMV-RB/Large pocket (LP) as previously described (Arap et al., 1997) . In both CDKN2A-null cell lines, U-87MG (Figure 3a ) and U-251MG ( Figure  3b) , a marked and sustained inhibition of pRB phosphorylation by p16
INK4a and p15 INK4b was apparent by 12 h post-transfection. In contrast, the inhibition of pRB phosphorylation by p16b was delayed to more than 48 h in U-87MG cells (Figure 3a) and to more than 72 h in U-251MG cells (Figure 3b) . Moreover, the magnitude of the inhibition of pRB/LP phosphorylation was much less pronounced in U-87MG cells (Figure 3a) and almost negligible in U-251MG cells (Figure 3b ). Taken together, these results in CDKN2A-null cells indicate that pRB, the substrate of the CDK/ cyclin D complexes, remains mostly phosphorylated despite p16b replacement.
In RB-negative LN-319 cells, phosphorylation of pRB was absent througout the time course, and only negligible eects of any of the cotransfections were apparent (Figure 3c ). Thus, under all of the conditions of this experiment, the RB-negative LN-319 glioma cells appeared unable to phosphorylate the exogenously transfected pRB/LP (Figure 3c ). It is conceivable that the expression of the endogenous CDKN2Aa and/or CDKN2B genes is enough to suppress phosphorylation of the transfected amounts of pRB/LP. Although the absence of pRB/LP phosphorylation in LN-319 cells cotransfected with empty control vector still represents an apparent paradox, other examples of RB-negative cells unable to phosphorylate pRB have been described A possible explanation is that these cells may have additional genetic alterations downstream from RB. Alternatively, cell cycle progression may be driven by other regulators such as cyclin E, which can induce Sphase without activation of the RB-E2F pathway ). A molar ratio of 1 : 15 (pCMV-RB/LP: test construct) was used in each of the transfections. Control vector alone (no pCMV-RB/LP) was used in mock transfections. pRB/ LP was immunoprecipitated, separated by 8.5% SDS ± PAGE, and detected by immunoblotting. In each cell line, the relative ppRB/ LP: pRB/LP ratios at 12, 24, 48, and 72 h post-transfection were compared. In general, pRB/LP migrated as a tight band in resting cells and a series of four to ®ve bands in proliferating cells. At 12 h post-transfection, both p16
INK4a and p15 INK4b totally prevented pRB/LP phosphorylation while p16b appeared unable to prevent pRB/LP phosphorylation post-transfection until at least 48 h in (a) U-87MG or until more than 72 h in (b) U-251MG cells. Aside from this apparent dierence, the magnitude of pRB/LP phosphorylation inhibition also appeared comparatively slighter upon p16b cotransfection. (c) In RB-negative LN-319 cells, phosphorylation of pRB/LP was absent under all conditions throughout the time course (Lukas et al., 1997) . Either of these situations would render pRB phosphorylation status irrelevant. Consistent with these scenarios are our preliminary observations that LN-319 glioma cells transfected with a fulllength RB cDNA are not growth suppressed (unpublished data).
Glioma-derived CDKN2A exon 2 mutations do not disrupt p16b activity
We next sought to determine the eects of mutations originally described for exon 2 of CDKN2A, which is the sequence shared between p16
INK4a and p16b. We used a series of seven well characterized glioma-derived CDKN2A exon 2 mutations (Arap et al., 1997) corresponding to R87H, A112V, R120H, A121V, G125R, A128A and A128V in the CDKN2Ab reading frame. Figure 4 shows the growth suppressive eects of these mutant alleles compared to those of empty control vector, wild-type CDKN2Ab, wild-type CDKN2Aa (p16
INK4a
), and CDKN2B (p15
INK4b
) in each of the three glioma cell lines. These results suggest that the altered exon 2 alleles tested contain only non-inactivating point mutations in the CDKN2Ab reading frame, since no clear loss-offunction was noted in these growth suppression assays of U-87MG (Figure 4a ), U-251MG (Figure 4b ) and LN-319 (Figure 4c ).
To demonstrate that the growth inhibitory eects were not a consequence of dierential expression of the CDKN2Ab alleles, we analysed transfectants of cells with CDKN2A-null backgrounds (U-87MG and U-251MG) and CDKN2A-wild-type background (LN-319). Cells were harvested and analysed 7 ± 10 days post-transfection using an exon 1b probe (p16b speci®c). No p16b RNA was detected in the vector transfected cells and the levels of the expected 1.0 kb transcript from the mutant CDKN2Ab alleles were similar to the wild-type in U-87MG (Figure 5a , upper panel) and in U-251MG cells (Figure 5b, upper panel) . Moreover, in LN-319 cells, the levels of expression from the transfected 1.0 kb transcript are roughly comparable to the levels from the endogenous 0.9 kb transcript (Figure 5c, upper panel) . Equal loading of RNA in each lane (Figure 5a , b and c, lower panels) was demonstrated by methylene blue staining of ribosomal RNA (Herrin and Schmidt, 1988) . Thus, we observed abundant and speci®c p16b mRNA in all three transfected glioma cell lines.
Discussion
Chromosome 9p21 deletions are common in malignant gliomas, suggesting the presence of one or more tumor suppressor genes within that region. The tumor suppressor gene CDKN2A, which encodes the cyclindependent kinase inhibitor p16
INK4a appears to be a critical target of these deletions (reviewed in Sherr, 1996) . The CDKN2B gene, which encodes the cell cycle regulator p15
INK4b also maps to chromosomal region 9p21, in tandem to the CDKN2A gene. However, CDKN2B is an unlikely glioma suppressor gene candidate since (i) deletions of p15
INK4b appear to usually occur with concomitant deletion of p16 Vector ,  p16b WT,  R87H,  A112V,  R120H,  A121V,  G125R,  A128A,  A128V,  p16   INK4a , p15
INK4b RB-independent p16b-mediated glioma cell suppression W Arap et al CDKN2B gene is not targeted by inactivating mutations in malignant gliomas (Jen et al., 1994) and other tumors (Sherr, 1996) . In addition to p16
INK4a
, the CDKN2A gene also encodes another transcript from an upstream initiation site encoding a dierent ®rst exon (exon 1b) joined to the splice acceptor site used in exon 2, but in an alternative reading frame (Duro et al., 1995; Quelle et al., 1995; Mao et al., 1995; Stone et al., 1995) . Thus, while the a transcript encodes p16
, the b transcript encodes an unrelated product (human p16b, murine p19 ARF ) Quelle et al., 1995) , a relatively unique situation in mammalian cells. Due to its chromosomal location, growth suppressive eects in other cell types, and the presence of some intragenic point mutations which had no signi®cant eect in p16
INK4a function, we reasoned that p16b might be an additional glioma cell growth suppressor, and that its mutational inactivation may also contribute to malignant glioma genetic progression. Therefore, we tested the glioma cell growth suppressive activity of wild-type p16b, and a series of glioma-derived mutant CDKN2Ab alleles for loss-of-function and found that these mutations appear to target p16
INK4a exclusively. Although the molecular pathway by which p16b exerts its growth suppression remains unknown Quelle et al., 1995) , our results support the hypothesis that p16b-mediated growth suppression in human malignant glioma cells is pRB-independent.
The data from our stable gene transfer assays (Figure 1) indicating that p16b is a glioma cell growth suppressor is consistent with similar p16b growth inhibitory eect reported in NIH3T3 cells (Quelle et al., 1995) , in head and neck cancer cells, and in HeLa cervical carcinoma cells, in which pRB is nonfunctional due to expression of E7 papillomavirus protein . While the in vitro studies performed here suggest that p16b is not a direct inhibitor of the targets of p16
INK4a (Figure 2) , similarly to what has been reported for the murine p19 ARF (Quelle et al., 1995) , this type of analysis is limited in that it can only test a known cyclin/CDK complex added to each individual reaction mix. Thus, time courses of an in vivo inhibition of RB phosphorylation assay (Arap et al., 1997) were used, and the comparatively minor eects of p16b replacement on inhibition of pRB phosphorylation observed in CDKN2A-null cells (Figure 3a and b) indicate that these eects are likely to be secondary to cell growth arrest via a distinct pathway. Although there appears to be a correlation between the degree of pRB phosphorylation inhibition (Figure 3a and b) and growth suppressive eects by p16b in the CDKN2A-null cells (Figure 1a) , it is unlikely that there is a direct cause-eect correlation since LN-319 cells, which are RB-negative and appear unable to phosphorylate exogenous pRB (Figure 3c ), are still subjected to pronounced growth suppression by p16b expression (Figure 1 ). It has long been known that RB phosphorylation can be indirectly in¯uenced by a variety of agents such as mitogens, growth suppressors and dierentiation inducers (reviewed in Wang et al., 1994) . Thus, it is possible that p16b indirectly aects RB phosphorylation by promoting the withdrawal of proliferating cells from the cell cycle rather than by directly preventing pRB phosphorylation as p16
.
Most of the p16
INK4a mutations described in human cancers are located within exon 2 of the CDKN2A gene. Therefore, they simultaneously alter the primary sequence of p16
INK4a and p16b. In contrast, sequence analysis of a large series of human tumors revealed no speci®c mutations located in exon 1b (Mao et al., 1995) . We have recently reported a panel of naturally occurring CDKN2A glioma-derived missense mutations (Arap et al., 1997) , ®ve of which were noninactivating point mutations (so-called`p16W' mutations, for wild-type behavior) for p16
INK4a Ranade et al., 1995) .
We reasoned that these p16W mutations might actually represent inactivating mutations in p16b. The data reported here, however, does not support this interpretation, since no clear loss-of-function point mutations were identi®ed amongst seven exon 2 mutant human glioma-derived CDKN2Ab alleles (Figure 4) . At the same time, two p16 INK4a loss-of-function mutations (W110* (Moulton et al., 1995) and P114L (Ueki et al., 1994) ) in the corresponding CDKN2Aa alleles were demonstrated (Arap et al., 1997) . These collective data are consistent with a recent report of a murine CDKN2Ab mutation and deletion analysis in NIH3T3 ®broblasts, which concluded that p19 ARF exon 1b is`necessary and sucient' for its eect and that exon 2 mutations do not inactivate p19 ARF (Quelle et al., 1997) . Thus, it is likely that cancer-derived CDKN2A mutations speci®cally target p16
INK4a
, since exon 1b mutations have not been found in tumors (Mao et al., 1995) and the growth suppressive p16b function appears unaected to disruption by CDKN2A exon 2 cancer-derived point mutations. Although we have no explanation for the presence of mutations that do not aect the functions of either p16
INK4a (Arap et al., 1997) or p16b, these mutations do not appear to bestow selective growth advantages. Since these mutants were detected in only a minor proportion of a heterogeneous glioma population (Kyritsis et al., 1996) , it is unlikely that they have undergone clonal selection, and they might merely represent an end stage genetic event. Additional mutational analysis of p16b should further clarify this point.
In contrast to the larger murine protein (p19 ARF ) (Quelle et al., 1995) , human p16b has a predicted mw of 13.9 kD. Because of the lack of appropriate human antisera, it remains formally unproven whether the human transcript is translated Mao et al., 1995; Stone et al., 1995) . However, there have been recent reports of the identi®cation of a 14 kD p16b product (Sewell et al., 1997; Shores et al., 1997) . This question notwithstanding, our data support the conclusions that p16b is a growth inhibitor in human malignant glioma cells, and that it functions by an as yet undetermined biochemical pathway but independently from a functional RB protein.
It is conceivable that the dual utilization of coding sequences could explain why the frequency of 9p loss increases not only at the transition from astrocytoma to anaplastic astrocytoma but also at the transition from anaplastic astrocytoma to GBM, perhaps implying that the a and b products from the CDKN2A gene may play roles in distinct growth suppressive biochemical pathways at various stages of malignant glioma genetic progression. Although the absence of intragenic inactivating mutations suggests that p16b is unlikely to be a primary target for mutational inactivation in chromosome 9p21 deletions, a full understanding of the role of human p16b in malignant gliomas awaits elucidation of its gene regulation and con®rmation of its protein expression in vivo.
Materials and methods
Cell lines
The malignant glioma cell lines (U-87MG, U-251MG, LN-319, and LN-Z308) used in this study and their growth conditions were described previously (Arap et al., 1995 (Arap et al., , 1997 . CCD-43SK, a normal skin ®broblast cell line, was obtained from the American Type Culture Collection (ATCC).
by adding 500 ng of bacterially expressed GST-pRB-SspI/ End (SE, residues 768 ± 928) as a substrate, and 10 mCi of [g-32 P]ATP (3000 Ci/mMol, Amersham) for 30 min at 308C. Subsequent processing was done as described .
Assays of in vivo inhibition of pRB phosphorylation were done as described (Arap et al., 1997) with empty control vector, pCDKN2Aa, pCDKN2Ab, and pCDKN2b in U-87MG, U-251MG, and LN-319 glioma cells, which were harvested at 12, 24, 48, and 72 h post-transfection.
Metabolic labeling of serum starved, subcon¯uent U-251MG, LN-Z308, and LN-319 glioma cells was accomplished with [ 35 S]translabel (Amersham) overnight. Cells were lysed in ice-cold ELB + (*1 ml/100 mm dish). After preclearing with GST-beads, lysates were incubated with GSTbeads, GST-p16
INK4a
-beads, or GST-p16b-beads for 1 h at 48C, recovered by centrifugation, washed extensively, resolved in 4 ± 20% gradient SDS ± PAGE and detected bȳ uorography.
